Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation

Pediatric Critical Care Medicine

Volumn 15, Issue 2, 2014, Pages

  Liveris, Anna ^a   Bello, Ricardo A ^a   Friedmann, Patricia ^a   Duffy, Melissa A ^a   Manwani, Deepa ^a   Killinger, James S ^a   Rodriquez, Daniel ^a   Weinstein, Samuel ^a  

^a CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

Author keywords

Activated clotting time; Activated partial thromboplastin time; Blood coagulation tests; Extracorporeal membrane oxygenation

Indexed keywords

ADOLESCENT; ANTICOAGULANTS; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; EXTRACORPOREAL MEMBRANE OXYGENATION; FACTOR XA; FEMALE; HEPARIN; HUMANS; INFANT; INFANT, NEWBORN; INTENSIVE CARE UNITS, PEDIATRIC; MALE; NEW YORK; PARTIAL THROMBOPLASTIN TIME; RETROSPECTIVE STUDIES; WHOLE BLOOD COAGULATION TIME;

EID: 84894042669     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/PCC.0000000000000028     Document Type: Article

References (22)

1. Extracorporeal Life Support Organization: ECMO Registry of the Extracorporeal Life Support Organization (ELSO). Ann Arbor, MI, ELSO, 2012
2. Andrew M, Paes B, Milner R, et al: Development of the human coagulation system in the full-term infant. Blood 1987; 70:165-172
3. Monagle P, Barnes C, Ignjatovic V, et al: Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost 2006; 95:362-372
4. Oliver WC: Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth 2009; 13:154-175
5. Hirsh J, Raschke R: Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:188S-203S
6. Gruenwald CE, Manlhiot C, Abadilla AA, et al: Heparin brand is associated with postsurgical outcomes in children undergoing cardiac surgery. Ann Thorac Surg 2012; 93:878-882
7. Hattersley PG: Activated coagulation time of whole blood. JAMA 1966; 196:436-440
8. Bull BS, Korpman RA, Huse WM, et al: Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975; 69:674-684
9. Bull BS, Huse WM, Brauer FS, et al: Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975; 69:685-689
10. Martindale SJ, Shayevitz JR, D'Errico C: The activated coagulation time: Suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery. J Cardiothorac Vasc Anesth 1996; 10:458-463
11. Baird CW, Zurakowski D, Robinson B, et al: Anticoagulation and pediatric extracorporeal membrane oxygenation: Impact of activated clotting time and heparin dose on survival. Ann Thorac Surg 2007; 83:912-919
12. Uden DL, Payne NR, Kriesmer P, et al: Procedural variables which affect activated clotting time test results during extracorporeal membrane oxygenation therapy. Crit Care Med 1989; 17:1048-1051
13. Khaja WA, Bilen O, Lukner RB, et al: Evaluation of heparin assay for coagulation management in newborns undergoing ECMO. Am J Clin Pathol 2010; 134:950-954
14. Nankervis CA, Preston TJ, Dysart KC, et al: Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation. ASAIO J 2007; 53:111-114
15. Langdell RD, Wagner RH, Brinkhous KM: Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure. J Lab Clin Med 1953; 41:637-647
16. Basu D, Gallus A, Hirsh J, et al: A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287:324-327
17. Kitchen S, Jennings I, Woods TA, et al: Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol 1996; 49:10-14
18. Denson KW, Bonnar J: The measurement of heparin. A method based on the potentiation of anti-factor Xa. Thromb Diath Haemorrh 1973; 30:471-479
19. Streif W, Mitchell LG, Andrew M: Antithrombotic therapy in children. Curr Opin Pediatr 1999; 11:56-64
20. Junker R, Käse M, Schulte H, et al: Interferences in coagulation tests-Evaluation of the 570-nm method on the Dade Behring BCS analyser. Clin Chem Lab Med 2005; 43:244-252
21. Sievert A, Uber W, Laws S, et al: Improvement in long-term ECMO by detailed monitoring of anticoagulation: A case report. Perfusion 2011; 26:59-64
22. Chen A, Teruya J: Global hemostasis testing thromboelastography: Old technology, new applications. Clin Lab Med 2009; 29:391-407